# Retatrutide Achieves 16.8% Weight Loss in Phase 3 Clinical Trial

Canonical source: https://retacompare.com/research/retatrutide-achieves-16-8-weight-loss-in-phase-3-clinical-trial

Weight Loss Outcomes · 2026-03-20


    Retatrutide, a novel triple hormone drug developed by Eli Lilly, has demonstrated a significant weight loss of 16.8% in participants during a phase 3 clinical trial. This outcome highlights the potential of retatrutide as a therapeutic option for obesity management, particularly given the increasing prevalence of obesity-related health issues. The trial's results may pave the way for further research into the efficacy and safety of this medication.


What this source covers

The source discusses the results of a phase 3 clinical trial for retatrutide, a drug that targets multiple hormonal pathways involved in weight regulation. The trial reported an average weight loss of 16.8% among participants, indicating a promising therapeutic benefit for individuals struggling with obesity. This data is essential for understanding the drug's potential role in weight management strategies.


Why it matters for Retatrutide research

The findings from this clinical trial are significant as they contribute to the growing body of evidence supporting the use of retatrutide in obesity treatment. By demonstrating substantial weight loss, this research may influence clinical practice and encourage further studies to explore the long-term effects and safety profile of retatrutide. The results also underscore the importance of multi-hormonal approaches in addressing obesity, which is a complex and multifactorial condition.


Key findings or claims

Retatrutide achieved an average weight loss of 16.8% in the phase 3 trial.

The trial supports the drug's potential as an effective treatment for obesity.

Findings may influence future obesity management strategies and clinical practices.

The results highlight the importance of targeting multiple hormonal pathways in weight regulation.

Further research is needed to assess the long-term safety and efficacy of retatrutide.


Context and prior work

Retatrutide is part of a new class of medications that target the glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon pathways. Previous studies have indicated that drugs acting on these pathways can lead to significant weight loss and improvements in metabolic health. The current findings align with this literature, reinforcing the idea that multi-hormonal therapies may offer enhanced benefits compared to traditional single-hormone treatments. For a comprehensive overview of peptide therapies, including retatrutide, see the ultimate guide on peptide stacking.


Practical takeaways for researchers

Researchers should consider the implications of the phase 3 trial results for retatrutide in the context of obesity treatment. The significant weight loss observed suggests that further investigation into the drug's mechanisms and long-term outcomes is warranted. Additionally, the findings may prompt researchers to explore combination therapies that leverage the multi-hormonal approach demonstrated by retatrutide. For ongoing updates and insights, researchers can refer to the news section of the research library.


FAQ

What is retatrutide?

Retatrutide is a triple hormone drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon pathways to aid in weight loss.

How much weight loss was reported in the trial?

The phase 3 trial reported an average weight loss of 16.8% among participants.

What are the implications of these findings?

The findings suggest that retatrutide could be an effective treatment option for obesity, warranting further research into its long-term effects and safety.


Source: Google News · Business Today · published 2026-03-20.

## Sources

- Google News · Business Today: https://news.google.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